Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roy Koga

Family Medicine Hilo, HI Medical Doctor

NPI 1164511309 CMS profile 7141

670 Ponahawai St Ste 120, Hilo, HI 96720

Open in the dashboard

General payments

$19,660

923 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roy Koga of Hilo, HI is reported in the CMS Open Payments database as having received $19,660 across 923 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,138 30
2024 General $1,705 56
2023 General $2,639 100
2022 General $3,544 177
2021 General $3,924 203
2020 General $3,082 165
2019 General $3,628 192

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roy Koga
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Roy Koga were reported at $1,138. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Roy Koga Family Medicine median Middle half National median
2019 $3,628 $150 $41–$543 $163
2020 $3,082 $120 $32–$415 $114
2021 $3,924 $137 $35–$551 $132
2022 $3,544 $137 $37–$512 $149
2023 $2,639 $149 $42–$545 $160
2024 $1,705 $156 $44–$560 $164
2025 $1,138 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $4,541 152 payments
  2. Novo Nordisk Inc $2,131 118 payments
  3. Amarin Pharma Inc. $1,438 72 payments
  4. Amgen Inc. $1,323 49 payments
  5. Lilly USA, LLC $1,305 59 payments
  6. Pfizer Inc. $1,235 75 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $997 38 payments
  8. Janssen Pharmaceuticals, Inc $915 38 payments
  9. Kowa Pharmaceuticals America, Inc. $817 61 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $719 34 payments
  11. Other $4,238 227 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $19,610 915 payments
  2. Education $50 8 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $3,570 124 payments
  2. Ozempic $1,465 75 payments
  3. Vascepa $1,105 49 payments
  4. Kerendia $997 38 payments
  5. RYBELSUS $976 58 payments
  6. XARELTO $827 37 payments
  7. Livalo $817 61 payments
  8. Repatha $788 40 payments
  9. MOUNJARO $720 26 payments
  10. BREZTRI $684 16 payments
  11. Other $12,896 713 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$22,379

Medicare's payments for the services billed

Medicare patients

142

Average age 74

Services billed

376

68 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 31%
Arthritis 20%
Chronic kidney disease 17%
Ischemic heart disease 8%
Atrial fibrillation 8%
COPD 8%
Cancer 8%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$282 254 —
CAPLYTA
$217 — —
Kerendia
$209 23 —
MOUNJARO
$142 60 —
AIRSUPRA
$114 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

923 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record